A Post Graduate in Science faculty and has a wide experience spanning over 35 years in the field of manufacturing Bulk Drugs and Active Pharmaceutical Intermediaries
Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting
Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs
The collaboration is expected to facilitate access to world-class treatments and specialised care for Iraqi personnel
Ultra-high purity surfactant for biologics and parenteral drug formulations
The facility has been classified as Voluntary Action Indicated
Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices
Subscribe To Our Newsletter & Stay Updated